Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Thromboprophylaxis
100%
Hospitalization
100%
COVID-19
100%
Clinical Outcomes
100%
Apixaban
66%
Placebo
66%
Anticoagulation
33%
Thromboembolism
33%
Major Bleeding
33%
Clinically Relevant Non-major Bleeding
33%
United States
16%
Randomized Placebo-controlled Trial
16%
Prospective Randomized Trial
16%
Twice Daily
16%
Hispanic
16%
Venous Thromboembolism
16%
US Hospitals
16%
Drug Treatment
16%
Disease Severity
16%
SARS-CoV-2 Vaccine
16%
World Health Organization
16%
Decline Rate
16%
Increased Incidence
16%
Event Rate
16%
Lost to Follow-up
16%
Severity Score
16%
Thromboembolic Complications
16%
Extended Prophylaxis
16%
Primary Safety
16%
In(III)
16%
Medical Prevention
16%
Risk Prediction Score
16%
Arterial Thromboembolism
16%
Delta Variant
16%
Omicron Variant
16%
Placebo Groups
16%
Venous Thromboembolism Risk
16%
Post-hospital Discharge
16%
Incidence of Death
16%
Anticipated Events
16%
Nursing and Health Professions
Clinical Outcome
100%
Placebo
100%
COVID-19
100%
Bleeding
66%
Apixaban
66%
Thromboembolism
50%
Anticoagulation
33%
Venous Thromboembolism
33%
Hospital Discharge
16%
Contraindication
16%
Severe Acute Respiratory Syndrome
16%
Drug Therapy
16%
Disease Severity
16%
World Health Organization
16%
Efficacy
16%
Accident Prevention
16%
Clinical Trial
16%
Arterial Thromboembolism
16%
Medicine and Dentistry
COVID-19
100%
Thromboprophylaxis
100%
Placebo
100%
Apixaban
66%
Thromboembolism
50%
Bleeding
33%
Anticoagulation
33%
Venous Thromboembolism
33%
Major Bleeding
33%
Drug Therapy
16%
Controlled Clinical Trial
16%
Disease Severity
16%
COVID-19 Vaccine
16%
Omicron Coronavirus Variant
16%
Arterial Thromboembolism
16%
Contraindication
16%